Slingshot members are tracking this event:
Amgen's (AMGN) Phase 1 clinical trial evaluating AMG 510 in patients with previously treated KRAS G12C-mutated solid tumors Data Released at IASLC 2019
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Initial data from the Phase 1 study were presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) earlier this year. The additional follow-up in a larger group of patients being presented at WCLC includes a subset of 34 NSCLC patients enrolled, with 23 of the patients being evaluable for efficacy. Thirteen of the evaluable patients received the target dose of 960 mg once daily, of which seven (54%) achieved a partial response at one or more timepoints and six (46%) achieved stable disease, for a disease control rate of 100%.
Slingshot Insights Explained
Sep 08, 2019
Don’t see a project related to the catalyst you care about?
Related Keywords Amg 510, Kras-mutant Non-small Cell Lung Cancer